

REPÚBLICA DE COLOMBIA
SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

Resolución N° 22718

Ref. Expediente N° NC2019/0009020

Por la cual se otorga una Patente de Invención

EL SUPERINTENDENTE DE INDUSTRIA Y COMERCIO

en ejercicio de sus facultades legales, en especial de las conferidas en el numeral 24 del artículo 3° del Decreto 4886 de 2011, y

CONSIDERANDO:

Que mediante escrito radicado en esta Superintendencia el 21 de agosto de 2019, con el N° NC2019/0009020, por GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED, entró a fase nacional la solicitud de patente de invención titulada “DERIVADOS DE PIRAZOL COMO INHIBIDORES DE BROMODOMINIO.”, que corresponde a la solicitud internacional PCT/EP2018/054733 del 27 de febrero de 2018.

Que la solicitud fue publicada en la Gaceta de la Propiedad Industrial N° 870 el 30 de agosto de 2019, sin que se hubieran presentado oposiciones por parte de terceros.

Que realizado el examen de fondo mediante Oficio N° 18851, notificado el 30 de noviembre de 2021, se requirió al solicitante en los términos del artículo 45 de la Decisión 486 de la Comisión de la Comunidad Andina para que presentara respuesta a las observaciones de carácter técnico, relacionadas con la patentabilidad o cumplimiento de los requisitos establecidos por esta Decisión para la concesión de la patente.

Que el solicitante mediante escrito radicado bajo el N° NC2019/0009020 el 7 de abril de 2022, respondió oportunamente el requerimiento formulado y presentó las reivindicaciones 1 a 4 que reemplazan las originalmente presentadas. Se acepta este último capítulo reivindicatorio presentado, comoquiera que se ajusta a las prescripciones contenidas en el artículo 34 de la Decisión 486.

Que en virtud de lo dispuesto en el artículo 14 de la Decisión 486 expedida por la Comisión de la Comunidad Andina “*Los países miembros otorgarán patentes para las invenciones, sean de producto o de procedimiento, en todos los campos de la tecnología, siempre que sean nuevas, tengan nivel inventivo y sean susceptibles de aplicación industrial.*”

Que en el presente caso las reivindicaciones 1 a 4 incluidas en el radicado bajo el N° NC2019/0009020 el 7 de abril de 2022, cumplen los requisitos indicados en el considerando anterior, toda vez que se refieren a compuestos derivados de 1H-pirazol-3,5-dicarboxamida, que difieren del estado de la técnica más cercano, US20140179648, en la inclusión de un anillo de pirazol, en lugar de un anillo de piridazinona. Adicionalmente, esta diferencia no se encuentra sugerida en el estado de la técnica y, como consecuencia de ello, se evidencia el efecto de inhibir proteínas de bromodominio BET a concentraciones $plC_{50} \geq 5.0 \mu M$ en el ensayo de BRD4 BD2, para el tratamiento de enfermedades autoinmunitarias y/o inflamatorias, infecciones víricas y cáncer. Sumado a lo anterior, la materia reivindicada, es susceptible de aplicación industrial.



Resolución N° 22718

Ref. Expediente N° NC2019/0009020

En consecuencia, las reivindicaciones 1 a 4 cumplen los requisitos de novedad, nivel inventivo y aplicación industrial establecidos en la normatividad citada en precedencia y este Despacho encuentra procedente conceder para las mismas la patente solicitada.

Que de acuerdo con la modificación presentada por el solicitante en el escrito radicado bajo el N° NC2019/0009020 el 7 de abril de 2022 y teniendo en cuenta el objeto concedido, se modifica el título de la invención el cual quedará de la siguiente manera: “DERIVADOS DE 1H-PIRAZOL-3,5-DICARBOXAMIDA Y COMPOSICIONES QUE LOS CONTIENEN”.

Con fundamento en las anteriores consideraciones, el Superintendente de Industria y Comercio,

RESUELVE

ARTÍCULO 1: Otorgar patente de invención a la solicitud que entró en fase nacional en virtud del Tratado de Cooperación en Materia de Patentes (PCT), para la creación titulada:

“DERIVADOS DE 1H-PIRAZOL-3,5-DICARBOXAMIDA Y COMPOSICIONES QUE LOS CONTIENEN”

Clasificación IPC: C07D 231/14, C07D 403/12, C07D 401/14, C07D 405/14, C07D 401/12, C07D 403/14, C07D 405/12, C07D 413/12, C07D 417/12, C07D 471/04, A61K 31/415, A61K 31/4155.

Reivindicaciones: 1 a 4 incluidas en el radicado bajo el N° NC2019/0009020 el 7 de abril de 2022, de acuerdo con el anexo 1.

Titular: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED.

Domicilio: 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX TW8 9GS, REINO UNIDO DE LA GRAN BRETAÑA.

Inventores: Robert J. WATSON, Stephen John ATKINSON, Alexander G. PRESTON, Ian David WALL, Simon Christopher Cranko LUCAS, Jonathan Thomas SEAL, Emmanuel Hubert DEMONT, Lee Andrew HARRISON y Gemma Michele LIWICKI.

Prioridades N°: 1/03/2017, GB (REINO UNIDO DE LA GRAN BRETAÑA), 1703283.0.
6/10/2017, GB (REINO UNIDO DE LA GRAN BRETAÑA), 1716374.2.

Solicitud internacional N°: PCT/EP2018/054733

Fecha: 27 de febrero de 2018.

Vigente desde: 27 de febrero de 2018

Hasta: 27 de febrero de 2038.

ARTÍCULO 2: El titular tendrá los derechos y las obligaciones establecidos en la Decisión 486 de la Comisión de la Comunidad Andina y en las demás disposiciones legales vigentes sobre propiedad industrial, precisando que para mantener vigente la patente se deberá cancelar la tasa anual de mantenimiento, conforme lo dispone el artículo 80 de la referida norma comunitaria.




Resolución N° 22718

Ref. Expediente N° NC2019/0009020

ARTÍCULO 3: Notificar el contenido de la presente resolución a GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED, advirtiéndole que contra ella procede el recurso de reposición, ante el Superintendente de Industria y Comercio, el cual podrá ser interpuesto en el momento de la notificación o dentro de los diez (10) días hábiles siguientes a ella.

NOTIFÍQUESE Y CÚMPLASE

Dada en Bogotá D.C., el 25 de abril de 2022












ANDRÉS BARRETO GONZÁLEZ
SUPERINTENDENTE DE INDUSTRIA Y COMERCIO

Firmado digitalmente
por: ANDRÉS
BERNARDO BARRETO
GONZÁLEZ
Fecha: 2022.04.25
17:01:23 COT
Razón: Validez jurídica.
Ubicación: Bogotá,
Colombia.

ANEXO 1

REIVINDICACIONES CONCEDIDAS
















1. Un compuesto seleccionado de:
















Resolución N° 22718

Ref. Expediente N° NC2019/0009020















Resolución N° 22718

Ref. Expediente N° NC2019/0009020















Resolución N° 22718

Ref. Expediente N° NC2019/0009020















Resolución N° 22718

Ref. Expediente N° NC2019/0009020















Resolución N° 22718

Ref. Expediente N° NC2019/0009020
















Resolución N° 22718

Ref. Expediente N° NC2019/0009020
















Resolución N° 22718

Ref. Expediente N° NC2019/0009020

Resolución N° 22718















Ref. Expediente N° NC2019/0009020

















Resolución N° 22718

Ref. Expediente N° NC2019/0009020

Resolución N° 22718













Ref. Expediente N° NC2019/0009020

















Resolución N° 22718

Ref. Expediente N° NC2019/0009020
















Resolución N° 22718

Ref. Expediente N° NC2019/0009020















Resolución N° 22718

Ref. Expediente N° NC2019/0009020















Resolución N° 22718

Ref. Expediente N° NC2019/0009020














Resolución N° 22718

Ref. Expediente N° NC2019/0009020


Resolución N° 22718

Ref. Expediente N° NC2019/0009020

Resolución N° 22718

Ref. Expediente N° NC2019/0009020



o una sal farmacéuticamente aceptable del mismo.

2. Un compuesto de acuerdo con la reivindicación 1, que se selecciona entre

*N*⁵-((1*r*,4*S*)-4-hidroxiciclohexil)-*N*³-metil-1-((*S*)-1-feniletil)-1*H*-pirazol-3,5-dicarboxamida;

*N*⁵-((1*R*,3*R*,5*S*,6*r*)-3-hidroxibiciclo[3.1.0]hexan-6-il)-*N*³-metil-1-((*S*)-1-feniletil)-1*H*-pirazol-3,5-dicarboxamida;

*N*⁵-((1*R*,5*S*,6*r*)-3-oxabicyclo[3.1.0]hexan-6-il)-1-((*S*)-1-(4-clorofenil)etil)-*N*³-metil-1*H*-pirazol-3,5-dicarboxamida;

(*S*)-*N*³-metil-1-(1-feniletil)-*N*⁵-(1*H*-pirazol-4-il)-1*H*-pirazol-3,5-dicarboxamida;

Resolución N° 22718

Ref. Expediente N° NC2019/0009020

1-((S)-1-(4-clorofenil)etil)-N⁵-((1R,3R,5S,6r)-3-hidroxiciclo[3.1.0]hexan-6-il)-N³-metil-1H-pirazol-3,5-dicarboxamida;


1-((S)-1-(3-clorofenil)etil)-N⁵-((1R,3R,5S,6r)-3-hidroxiciclo[3.1.0]hexan-6-il)-N³-metil-1H-pirazol-3,5-dicarboxamida;

N⁵-((1R,3R,5S,6r)-3-hidroxiciclo[3.1.0]hexan-6-il)-N³-metil-1-((S)-1-fenilpropil)-1H-pirazol-3,5-dicarboxamida; y

N⁵-((1r,4S)-4-metoxiciclohexil)-N³-metil-1-((S)-1-feniletil)-1H-pirazol-3,5-dicarboxamida

o una sal farmacéuticamente aceptable del mismo.

3. Un compuesto de acuerdo con la reivindicación 1, que es N⁵-((1R,5S,6r)-3-oxabicyclo[3.1.0]hexan-6-il)-N³-metil-1-((S)-1-feniletil)-1H-pirazol-3,5-dicarboxamida representado por la fórmula



o una sal farmacéuticamente aceptable del mismo.

4. Una composición farmacéutica que comprende un compuesto o una sal farmacéuticamente aceptable del mismo como se definen en las reivindicaciones 1-3 y uno o más excipientes farmacéuticamente aceptables.

